- Home
- KOD vs BSM Comparison
KOD vs BSM Comparison
Compare KOD & BSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOD | BSM |
|---|---|---|
| Founded | 2009 | 1876 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KOD | BSM |
|---|---|---|
| Price | $45.52 | $14.07 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $35.43 | $14.00 |
| AVG Volume (30 Days) | ★ 1.1M | 392.5K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 8.39% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $469,919,000.00 |
| Revenue This Year | N/A | $11.03 |
| Revenue Next Year | N/A | $9.63 |
| P/E Ratio | ★ N/A | $12.82 |
| Revenue Growth | N/A | ★ 8.35 |
| 52 Week Low | $3.33 | $11.90 |
| 52 Week High | $47.84 | $15.49 |
Technical Indicators
Market Signals| Indicator | KOD | BSM |
|---|---|---|
| Relative Strength Index (RSI) | 63.05 | 44.31 |
| Support Level | $21.82 | $13.41 |
| Resistance Level | $45.60 | $15.33 |
| Average True Range (ATR) | 3.11 | 0.29 |
| MACD | -0.39 | 0.06 |
| Stochastic Oscillator | 71.41 | 64.72 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
About BSM Black Stone Minerals L.P.
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests. The company owns mineral interests in approximately 16.9 million gross acres.